NeuroBasic-PharmaPhenomics wants to build new rodent models of neurological and psychiatric diseases and translate preclinical studies of animal models into novel treatments for human patients.

Mission

NeuroBasic-PharmaPhenomics is part of the Drugs cluster. The Drugs cluster offers the platform for the integrated approach necessary for the development of effective and safe new drugs to increase health. These activities are carried out with a simultaneous focus on economic benefits to ensure wealth for the Dutch economy: jobs, (foreign) investments, and increased entrepreneurial activity.

The Drugs cluster will deliver partnership, patents, publications, and projects moving into clinical development. In addition the Drugs cluster will create a new generation of research professionals and further international expansion. The Drugs cluster builds on the strong take off of TI Pharma and consolidates and aligns scattered initiatives, including selective continuity for research in three successful BSIK consortia: Neuro-BSIK, Virgo, and CDC. The chosen research lines were selected on excellence and their fit with the Drugs cluster focus (guided by the World Health Organization’s Priority Medicines report).
The Drugs cluster consists of four research lines and three strategic actions for the project portfolio development of TI Pharma:

- NeuroBasic-PharmaPhenomics (line 1): Developing drug discovery strategies in the field of neurology
- NeuroBasic-PharmaPhenomics (line 2): Developing drug discovery strategies in the field of psychiatry
- Viral infections: Discovering new viruses, building on knowledge of molecular prognostic, diagnostic, and therapeutic markers in viral infections and unraveling the underlying mechanisms of mutual host-virus interactions, with the overall purpose of developing better (more timely and effective) interventions for acute and chronic viral infections

The NeuroBasic project builds on the achievements of the NeuroBSIK-MousePhenomics consortium.

**Consortium History**

March 2011: Kickoff meeting held

**Structure & Governance**

Apart from the overall managerial Work Packages (WPs) to warrant the interactions among the WPs (WP0; WP leader Chris De Zeeuw), each of the two main research lines is divided into nine WPs that run in parallel. Each covers the various phases in the timelines and each as a designated WP leader.

**Links/Social Media Feed**

Homepage  [http://www.neurobasic.nl/](http://www.neurobasic.nl/)
Points of Contact

Annemieke Steenbergen
Project Manager
PO Box 71033
1008 BA Amsterdam
The Netherlands
phone: +31 (0)20 598 35 55
mobile: +31 (0)6 42 26 55 14
e-mail: annemieke.steenbergen@sylics.com
website: www.sylics.com

Sponsors & Partners

Delta Phenomics BV
Erasmus MC Rotterdam
Griffin Discoveries BV
Ministry of VWS
Neurasmus BV
Noldus Information Technology BV
Psynova Neurotech LTD
Sylics
UMC Utrecht
VU Amsterdam
VU University Amsterdam
Wageningen University & Research Centre

Updated: 04/08/2016